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Abstract
Background: Glucocorticoids are associated with increased fracture risk and are the mainstay of treatment in
polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, fracture risk in these conditions has not
been previously quantified. The aim of this study was to quantify the risk of fracture among patients with
PMR and GCA.
Methods: A retrospective cohort study was conducted using primary care records from the UK-based Clinical Practice
Research Datalink. Individuals aged 40 years and over, with incident diagnoses of PMR or GCA were separately identified
from 1990–2004 and followed up until 2015. For each exposed individual, four age-, sex- and practice-matched controls
were randomly selected. Incidence rates of fracture per 10,000 person-years were calculated for each disease group and
hazard rates were compared to the unexposed using Cox regression models.
Results: Overall, 12,136 and 2673 cases of PMR and GCA, respectively, were identified. The incidence rate of fracture was
148.05 (95% CI 141.16–155.28) in PMR and 147.15 (132.91–162.91) in GCA per 10,000 person-years. Risk of fracture was
increased by 63% in PMR (adjusted hazard ratio 1.63, 95% CI 1.54–1.73) and 67% in GCA (1.67, 1.49–1.88) compared to
the control populations. Fewer than 13% of glucocorticoid-treated cases were prescribed bisphosphonates.
Conclusions: This study reports, for the first time, a similar increase in fracture risk for patients with PMR and GCA. More
needs to be done to improve adherence to guidelines to co-prescribe bisphosphonates. Further research needs to identify
whether lower glucocorticoid starting doses and/or aggressive dose reduction reduces fracture risk.
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Background
Polymyalgia rheumatica (PMR) is the most common
inflammatory rheumatic disease in older people, whereas
giant cell arteritis (GCA) is the most common vasculitis.
Collectively, they are the most common indications for
long-term (greater than 6 months) glucocorticoid therapy
in primary care [1]. The two diseases have a marked over-
lap between them, with 16–21% of patients with PMR
developing GCA during the course of their illness and
40–60% of patients with GCA reporting PMR symptoms
[2]. Glucocorticoids remain the first-line recommended
treatment for GCA and PMR, and are a well-established
cause of osteoporosis and fragility fracture [3]. However,
in other inflammatory conditions, increased fracture risk
was also observed in patients not using glucocorticoids
[4–6], which may support a direct association between
inflammation and osteoporosis. Guidelines for the treatment
of GCA and PMR recommend early use of methotrexate as
a glucocorticoid-sparing agent in patients at increased risk
of glucocorticoid adverse effects [7]. Evidence is conflicting
as to whether methotrexate has a detrimental effect on bone
[8, 9]. However, the finding that cardiovascular events are
reduced in patients taking methotrexate [10] suggests that
better control of inflammatory burden by the drug may
reduce the risk of complications.
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Clinical guidelines for PMR management suggest bone
protection (bisphosphonate with calcium and vitamin D
supplementation) should be considered for all persons aged
over 65 years, patients with prior fragility fracture or those
requiring higher initial glucocorticoid dose [11], with GCA
guidelines suggesting bone protection for all [7].
To date, only one study has reported population-based
estimates of fracture risk in GCA in the context of other
glucocorticoid associated adverse events, reporting a
1.4-fold increased risk of fracture [12]. This study did
not examine the effect of age, glucocorticoid dose or
methotrexate on fracture risk and did not report risk at
individual fracture sites. There are no population-based
estimates of fracture risk in PMR. Other observational
studies examining the association between fracture and
PMR and/or GCA have been conducted with patients
recruited in secondary care [13–16]. Thus, the aim of
this study was to separately quantify the risk of fracture
among patients with PMR and GCA in a large primary care
dataset and assess the impact of age, sex, glucocorticoid
and methotrexate on risk.
Methods
Data source
We conducted a retrospective cohort study using data
from the Clinical Practice Research Datalink (CPRD), a
large database containing primary care medical records
of 6.9% of the United Kingdom (UK) population, repre-
sentative of the wider population in terms of age and sex
distribution [17]. Practices included in CPRD receive
training on recording clinical information, with data
from a practice being used only when it has reached a
certain standard of quality (up-to-standard; UTS). Patient
information is recorded using a coded thesaurus of clinical
terms (Read codes).
Study population
Separate exposed populations were defined for PMR and
GCA, which were not mutually exclusive. Patients with
PMR and/or GCA, aged 40 and over, were identified
based on the presence of one or more relevant Read
codes (Additional file 1: Table S1) documented in the
patient’s electronic medical record between 1990 and 2004.
Each patient was assigned an index date corresponding to
the date of their first recorded disease diagnosis. Those
diagnosed with PMR or GCA before the study period or
within 3 months of their registration with a practice were
considered prevalent cases and excluded [18].
Two control populations were separately defined for PMR
and GCA. Controls did not have a diagnosis of any inflam-
matory conditions (PMR, GCA, gout, ankylosing spondylitis,
inflammatory bowel disease, rheumatoid arthritis, systemic
lupus erythematous or psoriasis) recorded in their entire
electronic medical record up until the end of study. For each
exposed patient, four controls were randomly selected
matched on age, sex and general practice. The non-
exposed patient’s index date was defined as their matched
exposed patient’s index date.
Follow-up
The study start date was defined as the date of a patient’s
registration with their practice, the date their practice was
defined as UTS, the patient’s index date or on January 1,
1990, whichever came latest. The study end date was
defined as the earliest of the date of the patient’s death,
the date the patient transferred out of the practice, the
date of last data collection from that practice, the date of
first fracture, or August 31, 2015. Those with less than
12 months UTS data prior to index date and less than
3 years UTS follow-up after the index date were excluded.
Outcome definition
The event of interest was time from index date until first
fracture. As we were concerned with fragility fractures,
fractures at four sites encompassing the definition for
‘major osteoporotic fracture’ [19] were selected (vertebrae,
humerus, wrist and hip); we also included general codes
for fragility fracture where site was unspecified. First frac-
ture was identified using Read codes (Additional file 1:
Table S1), which have been previously validated in CPRD
[20]. In order to ensure this was the first fracture, patients
with a Read code for fracture prior to their index date
were excluded.
Covariates
We extracted information on patient demographics (age,
sex) at their index date, lifestyle-related characteristics
(body mass index (BMI), smoking status and alcohol con-
sumption) using the measurement nearest to their index
date (ever prior to index and up to 1 year after), comor-
bidities (summarised using the Charlson comorbidity
index [21]) and prescription of medications (gluco-
corticoid, methotrexate, bisphosphonates and proton
pump inhibitors (PPIs)) prior to the outcome for both
the exposed and non-exposed. BMI was categorised
according to the World Health Organization classification
as underweight (<18.5 kg/m2), normal (18.5–25 kg/m2),
overweight (25–29.9 kg/m2) or obese (≥ 30 kg/m2). Those
with missing information on BMI, smoking and alcohol
use were included as a separate category. Information on
falls was collected during the study period. Dose and dur-
ation of each glucocorticoid prescription was derived from
available information using the algorithm described in
Additional file 2, which was subsequently used to calculate
the average daily dose. Doses of oral glucocorticoid were
converted into a prednisolone-equivalent dosage. Where a
condition/prescription is present in the record, we assume
that the patient received this diagnosis/prescription at the
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time it was recorded. Where there is no record of a condi-
tion/prescription, it is assumed that the patient did not
have this condition/prescription.
Statistical analysis
All data summaries and analyses were performed separ-
ately for the PMR and GCA cohorts. Demographics and
lifestyle-related characteristics were summarised using fre-
quencies and percentages. Incidence rates were expressed
as the number of first fractures per 10,000 person years.
To assess the association between exposure and time to
osteoporotic fracture, Cox proportional hazard models
were used to obtain estimates of hazard ratios (HRs) with
95% confidence intervals (CIs), based on robust standard
errors to account for matching. Unadjusted estimates were
obtained followed by adjustment for age, sex, BMI, alcohol,
smoking, Charlson comorbidity index and PPI use. To
avoid over-adjustment, models were only adjusted for
confounding factors (associated with both the outcome
and exposure) which affected estimates by > 10%. Propor-
tionality of hazards assumption was tested throughout
using Schoenfeld residuals. Subgroup analyses by sex and
age group were performed. The timing of fracture reporting
in relation to PMR and GCA diagnosis was then assessed
by comparing the absolute rate of fracture at yearly inter-
vals up to 5 years after PMR/GCA diagnosis among the
exposed and non-exposed in terms of incidence rate ratios
using a Poisson regression model. Analyses were stratified
by fracture site. The effect of the use of methotrexate and
the cumulative dose of glucocorticoid on the incidence
of fracture was evaluated by estimating hazard ratios
within those with PMR/GCA, excluding the controls
without PMR/GCA from this analysis. Any methotrexate
use was compared to none and each quintile of average
daily glucocorticoid dose was compared to lowest quintile.
The analyses were adjusted as above, with the addition of
bisphosphonate use.
Sensitivity analyses were performed, defining the expos-
ure status as a Read code for PMR or GCA, plus two or
more prescriptions for glucocorticoids during the study
period; hence, patients who did not have two or more
glucocorticoid prescriptions were excluded, along with
their matched controls.
Patients with GCA may have symptoms of both PMR and
GCA, whereas patients with PMR would not be expected to
have symptoms of GCA; therefore, additional sensitivity
analysis was performed estimating the risk of fracture in the
group of patients with PMR diagnosis, excluding those with
GCA codes. Finally, analyses considering complete cases
only (no missing category for smoking, alcohol use and
BMI) were performed as sensitivity analyses and compared
to the main results.
All analyses were performed using Stata/MP 14.2 (Stata
Corporation, TX, USA).
Results
Basic characteristics
The study included 12,136 PMR and 2673 GCA patients,
individually matched to 46,238 and 10,423 non-exposed
patients (controls), respectively (Table 1). Of these, 735
patients were coded as having both conditions (6.1% and
27.5% of the PMR and GCA group, respectively). The
median follow-up for PMR and GCA patients was
9 years, corresponding to 114,082 and 25,212 person-
years of follow-up, respectively. Compared to controls,
PMR and GCA patients had higher BMI (> 30 kg/m2;
PMR: 32.6% vs. 29.0%; GCA: 15.6% vs. 13.6%). GCA, but
not PMR, patients were more likely to smoke than their
matched controls (GCA: 18.7% vs. 14.0%; PMR: 12.9%
vs. 13.1%) and patients with both conditions were more
likely to have consulted primary care for a fall within the
study period compared to their matched controls (PMR:
31.1% vs. 24.9%; GCA: 31.8% vs. 25.1%). As expected,
PPI, bisphosphonate and methotrexate prescriptions
were more common among PMR and GCA patients
compared to controls. Approximately 88% of PMR patients
and 83% of GCA patients had at least two glucocorticoid
prescriptions post-diagnosis.
Risk of fracture
A total of 1689 (13.9%) patients in the PMR group and 371
(14%) in the GCA group experienced a fracture, correspond-
ing to incidence rates of 148 (95% CI 141–155) and 147
(133–163) per 10,000 person-years, respectively (Table 2).
After adjustment, the risk of fracture was 63% higher in
patients with PMR (adjusted HR (aHR) 1.63, 95% CI 1.54–
1.73) and 67% higher in those with GCA (aHR 1.67, 95% CI
1.49–1.88) compared to their separate control populations.
Whilst the incident rate of fracture was higher in women
than men, in both the PMR and GCA cases, the relative
increased risk compared to controls was similar for both
sexes. Among those aged 50–60 years, the risk of fracture
was more than twice as high in patients with PMR or
GCA compared to their controls (PMR: aHR 2.23, 95%
CI 1.79–2.79; GCA: aHR 2.27, 95% CI 1.25–4.15). This
effect was less pronounced at older ages (test for trends
P < 0.001).
Figure 1 shows incidence rate ratio of fracture in the
years following PMR and GCA diagnosis compared to
controls. For patients with both conditions, the incidence
rate ratio of fracture remained significantly increased
5 years post-diagnosis.
Risk by fracture site
There was an increased risk of fractures at all sites in
PMR patients compared to controls. However, in GCA,
there was an increased risk of wrist, vertebra and hip
fractures, but not of humeral fracture (Table 3). In both
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conditions, the risk was greatest for vertebral fractures
(PMR: aHR 2.57, 95% CI 2.19–3.02; GCA: aHR 2.97,
95% CI 2.21–3.99).
Risk by prescriptions
Overall, 122 (4.6%) of patients with GCA and 706 (5.8%) of
those with PMR received a methotrexate prescription.
There were no significant differences in risk of fracture
between those prescribed, or not, methotrexate in either
group (PMR: aHR 0.96, 95% CI 0.75–1.21, GCA: aHR 1.36,
95% CI 0.84–2.19) (Table 4). Patients with PMR and GCA
received glucocorticoids for a median of 16 months (IQR
7–34) and 13 months (IQR 4–33), respectively. In both
conditions, patients in the highest quintile of glucocorticoid
average daily dose had a higher risk of fracture compared
to the lowest quintile (PMR: aHR 1.85, 95% CI 1.59–2.17;
GCA: aHR 2.09, 95% CI 1.46–2.99). Among GCA and
PMR patients with at least two prescriptions for glucocorti-
coids, only 12.6% and 10.1%, respectively, were prescribed
bisphosphonates.
Table 1 Basic characteristics of polymyalgia rheumatica (PMR) exposed/non-exposed and giant cell arteritis (GCA) exposed/non-exposed,
stratified by steroid use in the 1-year period prior to outcome
PMR GCA
Variables Present N = 12,136
n (%)
Non-present N = 46,238
n (%)
Present N = 2673
n (%)
Non-present N = 10,423
n (%)
Follow up time; median (IQR) 9.27 (5.74–12.36) 9.59 (5.97–12.61) 9.13 (5.87–12.38) 9.97 (6.23–13.00)
Total fractures 1689 (13.92) 5173 (11.19) 371 (13.88) 1,142 (10.96)
Fracture site
Wrist 464 (27.47) 1568 (30.31) 118 (31.81) 356 (31.17)
Vertebra 276 (16.34) 482 (9.32) 72 (19.41) 123 (10.77)
Humerus 220 (13.03) 693 (13.40) 35 (9.43) 145 (12.70)
Hip 563 (33.33) 1844 (35.65) 115 (31.00) 419 (36.69)
Other 166 (9.83) 586 (11.33) 31 (8.36) 99 (8.67)
Male, n (%) 3729 (30.73) 14,078 (30.45) 774 (28.96) 2981 (28.60)
Mean age (SD) 72.04 (9.70) 71.49 (9.52) 71.12 (9.91) 70.69 (9.76)
Body mass index, kg/m2
< 18.5 161 (1.33) 676 (1.46) 42 (1.57) 140 (1.34)
18.5–25 3723 (32.55) 14,031 (30.35) 795 (29.74) 3102 (29.76)
25–30 3950 (32.55) 13,401 (28.98) 844 (31.58) 2941 (28.22)
> 30 1919 (15.81) 6200 (13.41) 417 (15.60) 1412 (13.55)
Missing 2383 (19.64) 11,930 (25.80) 575 (21.51) 2828 (27.13)
Current smoker
Yes 1568 (12.92) 6045 (13.07) 500 (18.71) 1454 (13.95)
No 9286 (76.52) 32,579 (70.46) 1858 (69.51) 7111 (68.22)
Missing 1282 (10.56) 7614 (16.47) 315 (11.78) 1858 (17.83)
Alcohol (units per week)
Never/Ex-drinker 2972 (24.49) 10,000 (21.63) 708 (26.49) 2329 (22.34)
1–9 3285 (27.07) 12,087 (26.14) 705 (26.37) 2589 (24.84)
≥ 10 1453 (11.97) 5247 (11.35) 275 (10.29) 1105 (10.60)
Missing 4426 (36.47) 18,904 (40.88) 985 (36.85) 4400 (42.21)
Consultation for falls 3771 (31.07) 11,504 (24.88) 849 (31.76) 2612 (25.06)
Charlson comorbidity index; median (IQR) 3 (1–4) 1 (0–3) 2 (1–4) 1 (0–3)
Proton pump inhibitors 7715 (63.57) 20,710 (44.79) 1749 (65.43) 4670 (44.80)
Bisphosphonate 1479 (12.19) 829 (1.79) 413 (15.45) 194 (1.86)
Methotrexate 706 (5.82) 211 (0.46) 122 (4.56) 53 (0.51)
> 1 Glucocorticoid prescription after index 10,738 (88.48) 5894 (12.75) 2232 (83.50) 1443 (13.84)
Glucocorticoids treatment length; Median months (IQR) 15.74 (6.51–34.36) 0.99 (0.23–3.07) 12.93 (4.01–32.49) 1.05 (0.23–5.13)
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Sensitivity analyses
Restricting analyses to the cases with two or more prescrip-
tions for glucocorticoids did not alter the overall adjusted
estimates of fracture significantly (GCA: HR 1.59, 95% CI
1.40–1.81; PMR: HR 1.62, 95% CI 1.53–1.73).
The risk of fracture was similar in PMR-only cases, i.e.
when cases with any GCA diagnoses were removed (PMR
only: HR 1.61, 95% CI 1.52–1.71).
When analysing complete cases only, results were similar
to when including a missing category for smoking, alcohol
use and BMI (results not presented).
Discussion
This is the first study to quantify the risk of fracture in
people with PMR and/or GCA, demonstrating an increased
risk of fracture of 63% in PMR and 67% in GCA when
compared with age-, sex- and practice-matched controls.
The increased risk was similar in men and women, and
highest for vertebral fractures, followed by wrist fractures.
We found that risk of fracture is highest within the first
year of diagnosis and remains significantly elevated for
more than 5 years after diagnosis. In both conditions, frac-
ture risk was higher in those who received a higher average
daily dose of glucocorticoids than in those who received a
lower daily dose. The median duration of steroid use was
less than 15 months for both conditions, although 25% of
patients with PMR had more than 34 months of treatment.
Less than 13% of glucocorticoid-treated patients had ever
received bone protection with a bisphosphonate. The use
of methotrexate was not associated with an increased risk
of fracture.
Strengths and limitations of the study
By utilising CPRD and selecting all incident cases of
PMR and GCA during the study period, our findings are
generalisable to the wider UK primary care population.
Matching cases and controls by age, sex and practice
reduces the likelihood of confounding. However, as in any
database study, it is possible that residual confounding
remains. Furthermore, our methods do not facilitate the
identification of asymptomatic or undiagnosed vertebral
fractures. Vertebral fractures often do not come to clinical
Table 2 Incidence rates and hazard ratios (HRs) for associations of fracture with exposure to polymyalgia rheumatica (PMR) and
giant cell arteritis (GCA)
Variables Present Non-present Unadjusted HR (95% CI) Adjusted HR (95% CI)a
Number with
fracture
Rate per 10,000
person-years (95% CI)
Number with
fracture
Rate per 10,000
person-years
PMR
Overall 1689 148.05 (141.16–155.28) 5173 115.67 (112.56–118.87) 1.29 (1.22–1.36) 1.63 (1.54–1.73)
Sex
Male 244 68.79 (60.68–77.99) 707 52.07 (48.37–56.06) 1.32 (1.15–1.53) 1.54 (1.33–1.81)
Female 1445 183.81 (174.57–193.54) 4466 143.4 (139.25–147.67) 1.29 (1.22–1.37) 1.61 (1.52–1.72)
Age in years
40–50 16 45.58 (27.93–74.41) 48 32.55 (24.53–43.2) 1.40 (0.81–2.41) 1.92 (1.01–3.69)
50–60 116 81.29 (67.77–97.52) 264 46.04 (40.81–51.94) 1.78 (1.43–2.2) 2.23 (1.79–2.79)
60–70 357 112.33 (101.26–124.61) 1018 78.56 (73.88–83.53) 1.44 (1.28–1.62) 1.85 (1.56–2.10)
70–80 753 161.12 (150.01–173.04) 2555 138.51 (133.25–143.99) 1.17 (1.08–1.26) 1.51 (1.38–1.64)
≥ 80 447 251.34 (229.08–275.75) 1288 210.89 (199.68–222.72) 1.21 (1.08–1.34) 1.61 (1.43–1.81)
GCA
Overall 371 147.15 (132.91–162.91) 1142 109.52 (103.35–116.06) 1.36 (1.22–1.53) 1.67 (1.49–1.88)
Sex
Male 49 66.62 (50.35–88.15) 127 42.37 (35.61–50.42) 1.59 (1.15–2.2) 1.62 (1.17–2.24)
Female 322 180.31 (161.66–201.12) 1015 136.6 (128.45–145.27) 1.34 (1.19–1.51) 1.67 (1.47–1.90)
Age in years
40–50 4 35.23 (13.22–93.86) 9 18.87 (9.82–36.26) 1.87 (0.63–5.58) 1.98 (0.66–5.94)
50–60 18 55.2 (34.78–87.61) 46 34.94 (26.17–46.65) 1.56 (0.9–2.71) 2.27 (1.25–4.15)
60–70 85 112.74 (91.15–139.45) 257 78.19 (69.19–88.36) 1.49 (1.17–1.89) 1.79 (1.40–2.30)
70–80 181 185.8 (160.61–214.94) 579 141.96 (130.85–154) 1.34 (1.13–1.57) 1.65 (1.39–1.95)
≥ 80 83 234.75 (189.31–291.1) 251 197.88 (174.85–223.94) 1.20 (0.93–1.54) 1.48 (1.13–1.94)
aAdjusted for confounding factors which affected the HR > 10%, from age, sex, BMI, alcohol consumption, smoking status, Charlson comorbidity index and PPI use
when not stratified by those
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attention [22], and it is theoretically possible that the pain
of GCA and/or PMR may mask the presentation of these
fractures; both of these factors may result in underestima-
tion of this risk. A number of further limitations of our
study are worthy of acknowledgement. First, we relied on
General Practitioner diagnoses of GCA and PMR. The
diagnosis of GCA has previously been validated in CPRD
[23], although PMR has not. Other conditions may be
misclassified as PMR, which may explain why 12% of
those with a PMR Read code were not treated with two or
more glucocorticoid prescriptions. However, a sensitivity
analysis which excluded these participants did not change
our findings, providing confidence in our estimates. Second,
we excluded patients without 3 years of UTS follow-up
records after baseline, which may have resulted in the cases
being healthier and a potentially bias in our findings
towards the null hypothesis. Third, we cannot account for
drugs prescribed in secondary care, for example, parenteral
osteoporosis treatments and intravenous or intramuscular
glucocorticoids. However, in practice, oral glucocorticoids
remain the mainstay of treatment, intravenous glucocorti-
coids are more likely to be prescribed to those already on
Fig. 1 Incident rate ratios of fracture in GCA and PMR populations. Adjusted for confounding factors which affect the HR > 10%, from age, sex,
BMI, alcohol consumption, smoking status, Charlson comorbidity index and PPI use
Table 3 Incidence rates and hazard ratios (HRs) for associations of site-specific fracture with exposure to polymyalgia rheumatica
(PMR) and giant cell arteritis (GCA)
Variables Present Non-present Unadjusted HR (95% CI) Adjusted HR (95% CI)a
Number with
fracture
Rate per 10,000
person-years (95% CI)
Number with
fracture
Rate per 10,000 person-years
PMR
Wrist 464 40.67 (37.14–44.55) 1568 35.06 (33.37–36.84) 1.16 (1.05–1.29) 1.70 (1.52–1.90)
Vertebra 276 24.19 (21.50–27.22) 482 10.78 (9.86–11.78) 2.25 (1.94–2.61) 2.57 (2.19–3.02)
Humerus 220 19.28 (16.90–22.01) 693 15.50 (14.38–16.69) 1.25 (1.07–1.45) 1.63 (1.39–1.91)
Hip 563 49.35 (45.44–53.60) 1844 41.23 (39.39–43.16) 1.20 (1.10–1.32) 1.45 (1.31–1.60)
Unspecified 166 14.55 (12.50–16.94) 586 13.10 (12.08–14.21) 1.14 (0.96–1.35) 1.26 (1.06–1.51)
GCA
Wrist 118 46.80 (39.08–56.06) 356 34.14 (30.77–37.88) 1.37 (1.12–1.68) 1.84 (1.49–2.28)
Vertebra 72 28.56 (22.67–35.98) 123 11.80 (9.88–14.08) 2.44 (1.84–3.23) 2.97 (2.21–3.99)
Humerus 35 13.88 (9.97–19.33) 145 13.91 (11.82–16.36) 1.01 (0.70–1.45) 1.19 (0.81–1.73)
Hip 115 45.61 (37.99–54.76) 419 40.18 (36.51–44.22) 1.16 (0.95–1.42) 1.39 (1.13–1.72)
Unspecified 31 12.30 (8.65–17.48) 99 9.49 (7.80–11.56) 1.37 (0.91–2.05) 1.32 (0.87–2.00)
aAdjusted for confounding factors which affected the HR > 10%, from age, sex, BMI, alcohol consumption, smoking status, Charlson comorbidity index and PPI use
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high oral doses, intramuscular doses are unlikely to be pre-
scribed exclusively in secondary care, and the proportion of
patients on parenteral osteoporosis treatment is small.
Further, patients with GCA and PMR may have consulted
more frequently, resulting in ascertainment bias, particu-
larly relevant to the identification of vertebral fractures
which often go undiagnosed [22]. However, adjustment
for consultation rate made little difference to the results.
Finally, it was not possible to determine the inflammatory
burden associated with our conditions of interest. It is
theoretically possible that the inflammatory component of
GCA is more deleterious to bones than glucocorticoids,
and that when glucocorticoids effectively treat high levels
of inflammation, the fracture risk incurred by the gluco-
corticoids themselves is offset.
Comparison with other studies
Previous studies have demonstrated a dose-dependent
increase in fracture risk with glucocorticoid dose [3] and
these findings were mirrored in our study. However,
previous studies of fracture risk in patients treated with
glucocorticoids in CPRD suggest a rapid offset of increased
risk on treatment cessation, with most excess risk disap-
pearing within 1 year of stopping [3]. In our study, risk
persisted for more than 5 years after diagnosis, but we did
not compare rates before and after stopping. A previous
study using CPRD found a much lower relative risk (1.09)
of wrist fracture in glucocorticoid users [3]; higher rates of
wrist fractures in our study may have been due to the
increased number of falls recorded during the study
period. Rossini et al. [13] found that vertebral fractures
were more common than fractures at other sites in patients
with GCA; however, theirs was an observational study in
which patients had radiographs that would have resulted in
an increased detection of subclinical fractures in the spine.
The previous population study examining fracture risk in
GCA found a higher risk of fracture in men than women,
which is in contrast to our findings [12]. This may be
related to the inclusion of fractures at sites that are typically
traumatic, as opposed to fragility fractures. Other studies
have found much higher rates of bisphosphonate use; in
our study, the proportion of patients prescribed bispho-
sphonates was half of that in previous prospective primary
care cohorts of patients with PMR [24] or prescribed gluco-
corticoid generally [25], and one-sixth of the proportion
of patients with PMR treated with bisphosphonates in
secondary care [26]. This might be explained by changes
in practice over the dates of study inclusion, although UK
Table 4 Incident rates and hazard ratios (HRs) for association of fracture with methotrexate and glucocorticoid use among those
with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)
Variables Number of patients Number with fracture Rate per 10,000 person-years
(95% CI)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)a
PMR
Methotrexate
No 11,430 1614 151.32 (144.11–158.89) Reference Reference
Yes 706 75 101.03 (80.57–126.69) 0.65 (0.52–0.83) 0.96 (0.75–1.21)
Glucocorticoid average daily dose (quintiles)
Quintile 1 (1–4.9 mg) 2148 281 135.72 (120.74–152.55) Reference Reference
Quintile 2 (4.9–6.1 mg) 2148 286 139.86 (124.56–157.05) 1.03 (0.88–1.22) 1.12 (0.95–1.32)
Quintile 3 (6.1–7.5 mg) 2147 291 141.52 (126.16–158.75) 1.04 (0.88–1.23) 1.16 (0.99–1.37)
Quintile 4 (7.5–10.0 mg) 2148 283 141.32 (125.78–158.78) 1.04 (0.88–1.23) 1.27 (1.08–1.50)
Quintile 5 (10.0–73.3 mg) 2147 367 196.70 (177.57–217.89) 1.46 (1.25–1.71) 1.85 (1.59–2.17)
GCA
Methotrexate
No 2551 353 147.51 (132.90–163.73) Reference Reference
Yes 122 18 140.38 (88.45–222.82) 0.94 (0.58–1.50) 1.36 (0.84–2.19)
Glucocorticoid average daily dose (quintiles)
Quintile 1 (1.1–5.7 mg) 447 52 118.06 (80.96–154.93) Reference Reference
Quintile 2 (5.7–7.5 mg) 446 63 147.64 (115.33–188.99) 1.26 (0.87–1.81) 1.51 (1.05–2.19)
Quintile 3 (7.5–9.8 mg) 447 59 138.05 (106.85–178.18) 1.17 (0.81–1.70) 1.46 (1.00–2.12)
Quintile 4 (9.8–13.5 mg) 446 57 138.33 (106.70–179.34) 1.18 (0.81–1.71) 1.58 (1.08–2.30)
Quintile 5 (13.5–83.9 mg) 446 72 181.18 (143.81–228.25) 1.54 (1.08–2.20) 2.09 (1.46–2.99)
aAdjusted for confounding factors which affected the HR > 10%, from age, sex, BMI, alcohol consumption, smoking status, bisphosphonate use, Charlson comorbidity
index and PPI use. Patients not on glucocorticoids were excluded from this analysis
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guidance in 2002 advocated the use of bisphosphonates in
patients treated with > 7.5 mg prednisolone aged 65 and
over [27].
The finding that fracture risk in PMR and GCA is similar
is surprising given that considerably lower dose glucocorti-
coids are recommended for PMR than for GCA. If the UK
guidelines for typical dosing and duration of glucocorticoid
are followed, a patient with PMR would be expected to
receive half the cumulative dose of steroids as compared to
the cumulative dose a patient with GCA would be expected
to receive (2817.5 mg over 15 months compared with
5705 mg over 18 months) [28, 29]. Relatively little is known
about ‘real life’ steroid use in PMR and GCA; however, our
findings demonstrate that, PMR is, in practice, treated for a
longer duration than GCA. Furthermore, in PMR, which is
more likely to be treated exclusively by primary care physi-
cians than secondary care specialists (especially in the UK
where our study was based), daily doses are also likely to be
higher than those recommended; in a UK survey of 1249
randomly selected General Practitioners, over 40% reported
initiating doses of 30 mg of prednisolone or more, in excess
of the EULAR/ACR recommended starting dose of
between 15 and 25 mg [30, 31].
Conclusion
Our study has three important implications for clinical
practice. First, the bisphosphonate use in this study was
low and more needs to be done to improve adherence
to current guidelines. Second, it highlights that clini-
cians need to be mindful of falls risk in this population.
The persisting risk of fracture at 5 years and the higher
risk of wrist fractures seen herein may be explained by
an increase in falls observed during the study period.
Third, it raises important questions about the doses of
glucocorticoids used to treat PMR. We therefore sug-
gest more research is needed into optimal glucocorticoid
tapering regimes [11] to identify whether lower starting
doses and/or aggressive dose reduction reduces fracture risk,
particularly in PMR, and to explore the safety and benefit
of using non-glucocorticoid treatments and glucocorticoid
sparing agents in the treatment of these conditions.
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